Reviewed & approved by Dr. Nova Reyes · Last checked 2026-10-24. ← Back to Evidence Library

Glutathione

L-glutathione · reduced glutathione (GSH) · γ-L-glutamyl-L-cysteinylglycine · Tathion (Japan prescription injection)

Status: Approved for Adam Greene by Dr. Nova Reyes, 2026-10-24

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

---

1. What it is and what people claim it does

Glutathione (reduced L-glutathione, or GSH) is a tripeptide built from glutamate, cysteine, and glycine. Almost every human cell makes it in high concentrations to neutralize reactive oxygen species, recycle vitamins C and E, and bind toxic drug metabolites in the liver so they can be excreted.

Because glutathione given by mouth is partly broken down by gut enzymes before reaching the bloodstream, wellness clinics, IV lounges, compounding pharmacies, and gray-market peptide sites sell injectable vials, IV drips, and nasal sprays. Marketing claims fall into four main buckets:

• Cosmetic skin lightening ("glutathione glow" or whitening drips): Claimed to inhibit the pigment enzyme tyrosinase and shift melanin production from dark eumelanin toward lighter pheomelanin.
• Brain protection in Parkinson's disease: Post-mortem brain studies show lower reduced glutathione in the substantia nigra of people with Parkinson's disease, leading clinics to offer IV infusions or compounded nasal sprays.
• Liver support, "detox," and fatigue: Sold as an IV push or subcutaneous injection after alcohol use, illness, or environmental exposures.
• Chemotherapy side-effect protection: Used in oncology clinics in parts of Europe and Asia to protect peripheral nerves from platinum-based chemotherapy drugs.

In Japan, prescription injectable glutathione (Tathion) has been approved for decades for specific medical uses including acute poisoning, chronic liver disease, radiation therapy side effects, and hyperpigmentation disorders such as melasma. ^R18 In the United States, however, no injectable or nasal glutathione product is FDA-approved. ^R20

---

2. What the human evidence actually shows

The Open Peptide Project's reading: Moderate for preventing cisplatin or oxaliplatin nerve damage (hospital IV use), Limited for oral or topical skin lightening, Very limited (mixed results) for IV skin lightening, Parkinson's disease, and cystic fibrosis, Very limited for fatty liver disease, and No human data for subcutaneous wellness injections.

Indication	Route studied	Evidence rating	Summary of human studies
Cisplatin or oxaliplatin chemotherapy nerve damage	Hospital IV infusion (+ IM in 1 study)	Moderate	4 randomized trials (50, 151, 52, and 27 cancer patients) found less peripheral neuropathy (nerve damage in the hands and feet) and better treatment completion vs saline without lowering tumor response. R5–R8
Carboplatin + paclitaxel chemotherapy nerve damage	Hospital IV infusion	Very limited (mixed results)	1 multicenter Phase 3 randomized trial (185 cancer patients) found no benefit over saline on sensory neuropathy or acute pain. R9
Cosmetic skin lightening (oral or topical)	Oral capsules, buccal lozenge, topical lotion	Limited	2 randomized oral trials (60 participants each), 1 split-face topical trial (30 women), and 1 open-label lozenge study (30 women) showed modest reductions in instrument-measured skin melanin at selected body sites. R10–R13
Cosmetic skin lightening (IV infusion)	IV infusion	Very limited (mixed results)	1 open-label placebo-controlled trial (50 women; 9/25 dropped out on IV GSH) found fading visual-scale changes and reported liver dysfunction in 32% of IV recipients plus 1 anaphylactic shock. R14, R15
Parkinson's disease	IV infusion or intranasal spray	Very limited (mixed results)	After 1 unblinded 9-patient IV study reported motor gains, 3 double-blind randomized trials (21 IV; 30 and 45 intranasal) found no statistically significant symptom benefit over placebo. R1–R4
Cystic fibrosis lung disease	Nebulized inhalation	Very limited (mixed results)	1 randomized trial (153 patients) missed its primary lung-function (FEV1), exacerbation, and quality-of-life endpoints vs saline. R17
Nonalcoholic fatty liver disease (NAFLD)	Oral capsules	Very limited	1 single-arm open-label pilot (34 adults, 29 completers) reported lower blood ALT liver enzyme levels after lifestyle changes plus oral glutathione, with no placebo group. R16
Subcutaneous wellness, energy, or "detox" shots	Subcutaneous injection	No human data	No controlled human trials found.

Chemotherapy-induced peripheral neuropathy (platinum drugs)

Four randomized, double-blind, placebo-controlled oncology trials conducted in Italy and the United Kingdom tested hospital IV glutathione given immediately before cisplatin or oxaliplatin:

• Cisplatin in advanced gastric cancer (Cascinu et al., 1995): In 50 patients receiving cisplatin-based chemotherapy, clinically evident neuropathy after the full course occurred in 4 of 24 assessable patients (17%) in the glutathione arm versus 16 of 18 (89%) on saline placebo (p = 0.0001), with preserved sensory nerve conduction amplitudes and no reduction in tumor response rate (76% vs 52%). ^R5
• Cisplatin in ovarian cancer (Smyth et al., 1997): In 151 women receiving cisplatin, 58% of the glutathione group completed all planned cisplatin cycles without toxicity-forced discontinuation compared with 39% on control (p = 0.04), alongside better kidney creatinine-clearance preservation (74% vs 62%, p = 0.006) and statistically significant quality-of-life gains on peripheral neurotoxicity, vomiting, depression, and daily activity scores. ^R6
• Oxaliplatin in colorectal cancer (Cascinu et al., 2002; Milla et al., 2009): In 52 patients receiving oxaliplatin, moderate-to-severe (grade 2–4) neuropathy occurred in 2 of 21 assessable patients on glutathione versus 11 of 19 on saline at mid-course (p = 0.003), and 3 vs 8 after the full course (p = 0.004), with identical tumor response rates (26.9% vs 23.1%). ^R7 A second randomized trial in 27 colorectal cancer patients on FOLFOX4 adjuvant therapy similarly found less neurotoxicity on glutathione (p = 0.0037) with no change in platinum-DNA adduct formation in white blood cells. ^R8
• Negative Phase 3 trial with carboplatin and paclitaxel (Leal et al., 2014 — Alliance N08CA): When the North Central Cancer Treatment Group / Alliance for Clinical Trials in Oncology tested IV glutathione against saline placebo in 185 patients receiving paclitaxel and carboplatin (where nerve injury is driven largely by the taxane paclitaxel rather than cisplatin/oxaliplatin), there was no benefit on patient-reported sensory neuropathy (p = 0.21) or clinician-graded grade ≥2 neuropathy (p = 0.449; time to neuropathy slightly favored placebo, p = 0.039). ^R9

Cosmetic skin lightening (oral, topical, and IV)

Small clinical studies in Thailand and the Philippines have tested oral, buccal, and topical glutathione, while only a single methodologically weak trial in Pakistan has tested intravenous glutathione for skin lightening:

• Oral capsules (Arjinpathana & Asawanonda, 2012; Weschawalit et al., 2017): In 60 healthy Thai medical students randomized to oral reduced glutathione or placebo, skin-meter (Mexameter) melanin indices decreased slightly more with glutathione than placebo at 2 of 6 measured skin sites (right face p = 0.021; sun-exposed forearm p = 0.036), with all 60 completing the study. ^R10 A subsequent 3-arm randomized trial in 60 healthy Thai women (56 completers) comparing oral reduced glutathione, oral oxidized glutathione (GSSG), and placebo (study capsules supplied by Kyowa Hakko Bio Co.) reported a trend toward lower melanin index and UV spots and reduced wrinkle scores at some sites, without a dramatic uniform change in skin tone. ^R13
• Topical lotion (Watanabe et al., 2014) and buccal lozenges (Handog et al., 2016): A split-face randomized trial in 30 healthy Filipino women conducted and funded by Kyowa Hakko Bio Co. reported lower Mexameter melanin indices on the side of the face treated with oxidized glutathione lotion compared with placebo lotion (p < 0.001). ^R11 An open-label single-arm study of 30 Filipino women using a daily buccal glutathione lozenge with no control group also reported lower melanin index readings over the study period. ^R12
• Intravenous glutathione for skin lightening (Zubair et al., 2016, appraised in Sonthalia et al., 2016/2018 and Aloraini et al., 2026): Despite widespread med-spa marketing of "whitening IV drips," neurology and dermatology reviews note only one comparative trial of IV glutathione for skin lightening: an open-label, non-blinded Pakistani study of 50 healthy women assigned to IV glutathione or normal saline (25 per group). Nine of 25 women (36%) in the IV glutathione group dropped out, leaving 16 completers. Using a subjective visual color card (the Taylor hyperpigmentation scale) with no published statistical significance test, the authors reported visual lightening at the end of the injection course in 6 of 16 completers (37.5%) on IV glutathione versus 3 of 16 (18.7%) on saline, which faded after stopping to 1 of 16 (6.2%) versus 0% six months later. Worse, liver dysfunction was reported in 8 of 25 IV glutathione recipients (32%) and anaphylactic shock in 1 recipient (4%). ^{R14, R15}

Parkinson's disease

• Early open-label IV report (Sechi et al., 1996): In 9 patients with early, untreated Parkinson's disease given open-label IV glutathione with no control group, disability scores declined by 42% during the infusion period before gradually returning toward baseline over the next several months. ^R1
• Double-blind IV randomized trial (Hauser et al., 2009): In 21 patients with inadequately controlled Parkinson's motor symptoms randomized to IV glutathione (11 assigned, 10 evaluated) or placebo (10), Unified Parkinson's Disease Rating Scale (UPDRS) motor + activities-of-daily-living scores improved by a mean of 2.8 points more on glutathione during the infusion period (p = 0.32) and worsened by 3.5 points more after stopping (p = 0.54)—neither difference was statistically significant. ^R2
• Double-blind intranasal randomized trials (Mischley et al., 2015 and 2017): A Phase I/IIa safety trial in 30 patients with Parkinson's disease found intranasal glutathione spray tolerable over a multi-month course compared with saline. ^R3 A follow-up double-blind Phase IIb trial in 45 patients randomized to intranasal saline, lower-strength glutathione, or higher-strength glutathione found that all three groups improved, including placebo, and neither glutathione group was statistically superior to placebo. One participant in the higher-dose glutathione group developed cardiomyopathy. ^R4

Liver disease and cystic fibrosis

• Nonalcoholic fatty liver disease (Honda et al., 2017): In an open-label, single-arm Japanese pilot study of 34 patients with ultrasound-diagnosed NAFLD (29 completers) who first completed a diet-and-exercise run-in and then took oral glutathione (supplied by Kohjin Life Sciences, a Mitsubishi Corporation Life Sciences company), blood alanine aminotransferase (ALT) levels and triglycerides declined compared with pre-treatment baseline, with no placebo group to separate the supplement from ongoing lifestyle changes. Remember that a blood-marker change is not the same as a proven reduction in cirrhosis or liver events. ^R16
• Japan's legacy liver-disease approval (Tathion): Prescription injectable glutathione in Japan carries a legacy approval for "improvement of liver function in chronic liver disease," supported in its package insert by compiled domestic Japanese clinical reports from the late 1960s and 1970s (reporting improved liver tests in 76.8% [929/1,210] of chronic liver disease cases). ^R18
• Cystic fibrosis (Griese et al., 2013): In a 153-patient randomized, double-blind, placebo-controlled trial of inhaled nebulized glutathione (73 patients) versus saline (80 patients), there was no significant difference in the primary endpoint of forced expiratory volume in 1 second (FEV1 change p = 0.180; area under the curve p = 0.205), pulmonary exacerbations, quality of life, or sputum oxidative-stress markers. ^R17

Study details — click to expand all clinical trial rows (doses, schedules, outcomes, and side effects)

Study (Year)	Design & Population	Route, Dose & Schedule	Primary / Key Outcomes	Adverse Events & Dropouts	Funding & Disclosures
Cascinu et al. (1995) R5	Randomized, double-blind, placebo-controlled trial; 50 adults with advanced gastric cancer on weekly cisplatin regimen	IV + IM: 1.5 g/m² IV in 100 mL normal saline over 15 min immediately before cisplatin, plus 600 mg IM on days 2–5 each week, evaluated at 9 and 15 weeks	Neuropathy at 9 weeks: 0/25 vs 16/25 on placebo. Neuropathy at 15 weeks: 4/24 (17%) vs 16/18 (89%) on placebo (p = 0.0001). Tumor response rate: 76% vs 52%; fewer blood transfusions (32 vs 62).	1/25 GSH vs 7/25 placebo not assessable at week 15 due to disease progression/death; no GSH-attributed toxicity reported.	Hospital oncology study (Ospedali Riuniti, Pesaro, Italy); no industry funder disclosed in abstract.
Smyth et al. (1997) R6	Randomized, double-blind, placebo-controlled trial; 151 women with stage I–IV ovarian cancer on cisplatin (100 mg/m²)	IV: 3 g/m² IV over 15–30 min before each cisplatin cycle for up to 6 cycles (every 3 weeks) [UNVERIFIED: exact GSH g/m² dose from full text; abstract states 6 cycles of cisplatin 100 mg/m² +/- GSH]	Completed all 6 cisplatin cycles: 58% (GSH) vs 39% (control) (p = 0.04). Creatinine clearance preservation: 74% vs 62% (p = 0.006). Significant quality-of-life gains in peripheral neurotoxicity, vomiting, depression, hair loss, shortness of breath, and concentration. Tumor response: 73% vs 62% (p = 0.25).	Fewer toxicity-related treatment discontinuations in GSH arm (42% vs 61% stopped early).	ICRF Medical Oncology Unit, Edinburgh; Boehringer Mannheim Italia supplied glutathione [UNVERIFIED: funder detail from full text].
Cascinu et al. (2002) R7	Randomized, double-blind, placebo-controlled trial; 52 adults with advanced colorectal cancer on bimonthly oxaliplatin regimen	IV: 1,500 mg/m² IV in 100 mL normal saline over 15 min immediately before each bimonthly oxaliplatin infusion (evaluated at 4, 8, and 12 cycles)	Grade 2–4 neuropathy after 8 cycles: 2/21 (10%) vs 11/19 (58%) on placebo (p = 0.003). Grade 2–4 neuropathy after 12 cycles: 3 vs 8 patients (p = 0.004). Sural nerve conduction preserved on GSH; tumor response 26.9% vs 23.1%.	5/26 GSH vs 7/26 placebo not assessable at cycle 8 due to progression; no GSH-specific adverse events reported.	Academic oncology study (Parma, Italy).
Milla et al. (2009) R8	Randomized, placebo-controlled trial; 27 adults with colorectal cancer on adjuvant FOLFOX4	IV: 1,500 mg/m² IV before each oxaliplatin infusion across 12 cycles	Statistically significant reduction in cumulative neurotoxicity at cycle 12 vs saline (p = 0.0037); no reduction in leukocyte platinum-DNA adduct formation.	Dropouts not detailed in abstract; no GSH-attributed serious adverse events reported.	University of Turin, Italy.
Leal et al. (2014) — Alliance N08CA R9	Phase 3 randomized, double-blind, placebo-controlled trial; 185 adults receiving paclitaxel + carboplatin chemotherapy (94 GSH, 91 placebo)	IV: 1.5 g/m² IV over 15 min immediately before each chemotherapy infusion	No benefit: EORTC-QLQ-CIPN20 sensory neuropathy score p = 0.21; CTCAE grade ≥2 neuropathy p = 0.449 (time to grade ≥2 neuropathy favored placebo, p = 0.039); weekly paclitaxel acute pain favored placebo (p = 0.002); time to progression p = 0.63.	Apparent toxicities and completion rates similar between arms.	Funded by US National Cancer Institute (NCI / Alliance for Clinical Trials in Oncology).
Arjinpathana & Asawanonda (2012) R10	Randomized, double-blind, placebo-controlled trial; 60 healthy Thai medical students (ages 19–22; 30 GSH, 30 placebo)	Oral: 500 mg/day capsules in two divided doses (250 mg twice daily) for 4 weeks	Mexameter melanin index decreased at all 6 skin sites on GSH, reaching statistical significance vs placebo at 2 of 6 sites: right face (p = 0.021) and sun-exposed left forearm (p = 0.036).	0/30 GSH vs 0/30 placebo dropped out; mild GI/skin complaints rare and similar.	Chulalongkorn University, Bangkok, Thailand.
Watanabe et al. (2014) R11	Randomized, double-blind, split-face placebo-controlled trial; 30 healthy Filipino women (ages 30–50)	Topical: 2% (w/w) oxidized glutathione (GSSG) lotion applied to one side of the face and placebo lotion to the other side twice daily for 10 weeks	Lower Mexameter melanin index on GSSG-treated half-face vs placebo at week 10 (p < 0.001), plus higher stratum corneum moisture and smoothness scores.	0/30 dropped out; no marked adverse skin reactions reported.	Conducted and funded by Kyowa Hakko Bio Co., Ltd. (3 of 4 authors are company employees).
Handog et al. (2016) R12	Open-label, single-arm pilot study (no control group); 30 healthy Filipino women (ages 22–42, Fitzpatrick skin types IV–V)	Buccal lozenge: 500 mg glutathione lozenge once daily for 8 weeks	Statistically significant decrease in Mexameter melanin indices from baseline at weeks 2–8; 90% (27/30) rated moderate lightening on unblinded global assessment.	0/30 dropped out; no serious adverse events or laboratory abnormalities reported.	St. Luke's Medical Center & Asian Hospital, Manila.
Weschawalit et al. (2017) R13	Randomized, double-blind, placebo-controlled, 3-arm parallel trial; 60 healthy Thai women (ages 20–50; 20 per arm, 56 completers)	Oral: 250 mg/day reduced GSH, 250 mg/day oxidized GSSG, or placebo orally once daily for 12 weeks	Trend toward lower melanin index and UV spots vs placebo in generalized estimating equation analysis; significant wrinkle reduction at selected sites in GSH and GSSG arms.	4/60 withdrew overall (reasons not drug-related); no serious adverse events or blood chemistry abnormalities.	Study capsules supplied by Kyowa Hakko Bio Co., Ltd.; authors declared no personal financial conflicts.
Zubair et al. (2016) (via Sonthalia 2018) R14, R15	Open-label, non-blinded placebo-controlled trial; 50 healthy Pakistani women (ages 25–47; 25 IV GSH, 25 IV saline)	IV: 1,200 mg glutathione IV or normal saline infused over 30 min twice weekly for 6 weeks (12 infusions), followed at 2, 4, and 6 months post-treatment	Visual Taylor hyperpigmentation scale improvement at completion: 6/16 completers (37.5%) vs 3/16 (18.7%) on saline (no statistical test reported); faded to 18.7% vs 12.5% at 2 months, 18.7% vs 0% at 4 months, and 6.2% (1/16) vs 0% at 6 months.	9/25 (36%) dropped out in IV GSH arm. Liver dysfunction in 8/25 (32%) and anaphylactic shock in 1/25 (4%) of IV GSH recipients.	Published in J Pak Assoc Dermatol 2016;26:177–181; appraised in Sonthalia et al. 2018 (PMC5808366).
Sechi et al. (1996) R1	Open-label, single-arm study (no control group); 9 adults with early, untreated Parkinson's disease	IV: 600 mg IV twice daily for 30 days, then stopped and followed monthly for 2–4 months	42% decline in unblinded clinical disability scores at day 30 compared with baseline, gradually waning over 2–4 months after stopping.	0/9 dropped out; no serious adverse events reported in abstract.	University of Sassari, Italy.
Hauser et al. (2009) R2	Randomized, double-blind, placebo-controlled pilot trial; 21 adults with Parkinson's disease (11 IV GSH, 10 placebo)	IV: 1,400 mg IV or saline placebo three times weekly for 4 weeks, followed for 8 weeks post-treatment	No significant difference vs placebo: UPDRS ADL + motor score improved by 2.8 points more on GSH during the 4-week infusion period (p = 0.32) and worsened by 3.5 points more over the 8-week washout (p = 0.54).	1/11 GSH withdrew before post-randomization efficacy assessment for personal reasons; 0 withdrawals for adverse events in either group.	University of South Florida; co-authored by D. Perlmutter (who popularized IV GSH in clinical practice).
Mischley et al. (2015) R3	Phase I/IIa randomized, double-blind, placebo-controlled trial; 30 adults with Parkinson's disease (10 per arm)	Intranasal: 300 mg/day, 600 mg/day, or saline placebo divided into three daily intranasal doses for 3 months	Primary safety/tolerability criteria met in all 3 arms; no substantial differences in adverse event frequency, cognition, blood chemistry, or smell tests.	1/30 withdrew before completing 3 months; sinus irritation mild and comparable across arms.	Bastyr University / University of Washington; authors declared no conflicts of interest.
Mischley et al. (2017) R4	Phase IIb randomized, double-blind, placebo-controlled trial; 45 adults with Hoehn & Yahr stage 1–3 Parkinson's disease (15 per arm)	Intranasal: 300 mg/day (100 mg thrice daily), 600 mg/day (200 mg thrice daily), or saline placebo for 3 months, plus 1-month washout	Not superior to placebo: Total UPDRS improved within the high-dose group vs baseline (-4.6 points, p = 0.0025), but placebo also improved substantially and neither GSH dose significantly beat placebo.	1 participant in the 600 mg/day GSH arm developed cardiomyopathy; 42/45 completed the trial.	Funded by Michael J. Fox Foundation / Bastyr University.
Honda et al. (2017) R16	Open-label, single-arm, multicenter pilot study (no control group); 34 Japanese adults with ultrasound-diagnosed NAFLD (29 completers)	Oral: 300 mg/day orally for 4 months after a 3-month diet-and-exercise run-in	Serum ALT decreased significantly from pre-GSH baseline (median 12.9% drop), alongside lower triglycerides, non-esterified fatty acids, and ferritin.	5/34 did not complete protocol; no serious drug-related adverse events reported.	Glutathione supplied by Kohjin Life Sciences (Mitsubishi Corporation Life Sciences); authors declared no competing interests.
Griese et al. (2013) R17	Randomized, double-blind, placebo-controlled trial; 153 patients (ages ≥8 years) with cystic fibrosis (73 inhaled GSH, 80 placebo)	Inhaled: 646 mg in 4 mL via eFlow nebulizer every 12 hours for 6 months	Missed primary endpoint: No significant difference in 6-month FEV1 change (p = 0.180) or FEV1 AUC (p = 0.205), pulmonary exacerbations, quality of life, or sputum oxidative-stress markers (transient +100 mL FEV1 difference at month 3 faded by month 6).	Adverse events similar between GSH and placebo arms.	Academic multicenter study (Munich, Germany; NCT00506688).

---

3. Known risks, side effects, and long-term unknowns

Oral capsules, buccal (cheek-dissolving) lozenges, and topical lotions caused very few side effects in short human trials—mostly occasional mild gastrointestinal discomfort or transient skin irritation. ^R10–R13

Injectable, intravenous, and inhaled routes carry substantially higher risks:

• Bacterial endotoxin poisoning in compounded US injections (repeated FDA warnings in 2019 and 2026): Because glutathione is sold both as a food/supplement ingredient and as a pharmaceutical bulk substance, multiple US compounding pharmacies have mistakenly or improperly used dietary-supplement-grade glutathione powder containing high levels of bacterial endotoxin (lipopolysaccharide from Gram-negative bacteria) to make sterile IV or subcutaneous injections.
• In February and June 2019, the US FDA warned that 7 patients developed fever, chills, body aches, headache, nausea, vomiting, severe low blood pressure (hypotension), and hospitalization shortly after receiving compounded IV glutathione made from dietary-ingredient powder containing up to five times the safe endotoxin limit. ^R20
• On August 27, 2026, the FDA issued a second nationwide warning after at least 30 patients across multiple states suffered fever, chills, dizziness, pain, septic-shock-like reactions, and hospitalizations following IV glutathione infusions compounded from a dietary-supplement-grade lot. ^R20
• On October 1, 2026, Greenwich Rx (a Texas compounding pharmacy) issued a voluntary nationwide recall of 10 lots of compounded glutathione injection due to elevated endotoxin levels after 2 patients required emergency department care when a subcutaneous-labeled vial was infused intravenously. ^R20
• Anaphylaxis and severe hypersensitivity: Japan's official Tathion package insert lists anaphylaxis (pallor, drop in blood pressure, tachycardia, dyspnea) as a serious adverse reaction (<0.1%), alongside rash, loss of appetite, nausea, and vomiting. ^R18 The Pakistani IV skin-lightening trial also recorded 1 case of anaphylactic shock among 25 IV recipients (4%). ^R14
• Liver, kidney, thyroid, and severe skin reactions reported with IV whitening drips: In the Pakistani IV skin-lightening trial, 8 of 25 healthy women (32%) developed liver-test dysfunction of unspecified severity. ^R14 Public health advisories from the Philippines FDA (2011 and 2019) and recent dermatology safety reviews highlight reports of Stevens-Johnson syndrome and toxic epidermal necrolysis (life-threatening blistering skin reactions), thyroid dysfunction, kidney dysfunction or failure, and severe abdominal pain in people receiving high-dose IV glutathione for skin whitening, as well as sepsis, hepatitis B/C, HIV, and air embolism when drips are given in non-medical spas or at home. ^{R15, R19}
• Bronchospasm with inhalation: Inhaled or nebulized glutathione is strongly acidic unless buffered and can trigger coughing or acute airway constriction (bronchospasm), particularly in people with asthma or hyperreactive airways. ^{R15, R17}
• Cardiomyopathy signal in one Parkinson's trial: One participant in the high-dose intranasal arm of the 45-person Phase IIb Parkinson's trial developed cardiomyopathy during the study; whether it was related to glutathione is unknown. ^R4
• Long-term unknowns: Dermatologists have raised theoretical concerns that chronic systemic suppression of eumelanin (the darker, UV-protective form of skin pigment) in favor of pheomelanin could increase long-term vulnerability to sun damage and skin cancer, though no long-term human follow-up exists to test this. ^{R14, R15}

---

4. Regulatory and compounding status

Jurisdiction / Body	Current Status	Details
United States (FDA — Drugs & Supplements)	Oral: Dietary supplement (GRAS) Injectable / Nasal: Not FDA-approved	Oral L-glutathione has FDA GRAS (Generally Recognized as Safe) food/supplement notices. No injectable, IV, or intranasal glutathione drug is FDA-approved. FDA has issued consumer warnings against injectable skin-lightening products and seized unapproved imported glutathione kits. R20
United States (FDA — 503A & 503B Compounding)	503A Category 1 & 503B Category 1 (under evaluation)	Listed in Category 1 on both the FDA 503A Bulk Drug Substances List (updated May 14, 2026) and the 503B List (updated Mar 21, 2025). At the June 8, 2022 PCAC meeting, FDA staff recommended against adding glutathione to the 503A list across 20+ reviewed uses due to weak efficacy evidence; the advisory committee voted 8 Yes, 5 No, 1 Abstain in favor of inclusion. No final rule has been issued, so Category 1 interim policy still applies—strictly requiring pharmaceutical-grade (not dietary-supplement-grade) bulk substance. R20
Japan (PMDA)	Approved prescription injection (Tathion / タチオン注射用)	Approved for IM/IV use (approval nos. 21800AMX10590000 and 21800AMX10591000, package insert revised Sept 2024) for drug poisoning, acetonemic vomiting, chronic liver disease liver-function improvement, eczema/dermatitis/urticaria/melasma/post-inflammatory hyperpigmentation, hyperemesis gravidarum, corneal injury, and radiation-therapy side effects. Not approved for whole-body cosmetic skin whitening in healthy people. R18
Philippines (FDA Philippines)	Approved for cisplatin neurotoxicity only; public warnings against IV skin whitening	Approved as an adjunct to cisplatin chemotherapy. Philippine FDA Advisories No. 2011-004 and No. 2019-182 warn the public that IV glutathione is not approved for skin lightening and carries serious health hazards. R19
World Anti-Doping Agency (WADA 2026)	Substance not prohibited; hospital-sized IV drips banned under Method M2.2	Glutathione itself is not named on the 2026 Prohibited List. However, under Method M2.2, intravenous infusions or injections exceeding WADA's volume threshold are prohibited at all times unless legitimately received in hospital treatments, surgical procedures, or clinical diagnostic investigations. R21

---

5. Quality, contamination, and gray-market risks

The gap between a hospital-administered pharmaceutical product (such as Japan's Tathion or the sterile infusions used in European oncology trials) and what buyers get from wellness lounges or online peptide vendors is especially wide for glutathione:

1. Dietary-supplement powder sold or compounded as an injectable: As documented in the FDA's 2019 and August 2026 safety alerts and the October 2026 Greenwich Rx recall, bulk L-glutathione powder intended for oral capsules does not undergo bacterial endotoxin testing required for parenteral (injectable) drugs. When compounded into IV or subcutaneous vials, endotoxin survives standard 0.22-micron filter sterilization and can trigger immediate fever, rigors, hypotension, and septic-shock-like reactions. ^R20
2. Unapproved imported "whitening" kits: US FDA enforcement actions have intercepted unapproved imported injectable kits (such as Relumins and Tatiomax) marketed online for home or med-spa skin bleaching, which have never been reviewed by the FDA for sterility, identity, or actual glutathione content. ^R20
3. Rapid oxidation in solution: Reduced glutathione (GSH) oxidizes rapidly in water into oxidized glutathione disulfide (GSSG) when exposed to air, warmth, or neutral-to-alkaline pH. Multi-dose vials stored in a refrigerator after reconstitution—or pre-mixed nasal sprays shipped without cold-chain nitrogen purging—lose reduced GSH potency over days to weeks.

---

6. Who should be especially cautious

• Anyone considering IV or subcutaneous glutathione from a med-spa, IV lounge, or online vendor: Nearly 40 documented US patients have suffered acute endotoxin reactions (including emergency room visits and hospitalizations) from compounded glutathione injections since 2019, and unapproved IV whitening drips have caused anaphylaxis and liver-test abnormalities. ^{R14, R20}
• People with asthma or reactive airway disease: Inhaled or nebulized glutathione can provoke acute bronchospasm and coughing; injectable glutathione has also been linked to wheezing and anaphylaxis in susceptible individuals. ^{R15, R17, R18}
• Cancer patients receiving chemotherapy other than cisplatin or oxaliplatin (or without oncologist oversight): While hospital IV glutathione reduced nerve damage in four small cisplatin/oxaliplatin trials, it failed in a 185-patient Phase 3 carboplatin/paclitaxel trial, and oncology specialists caution against taking unprescribed high-dose antioxidants during chemotherapy or radiation without the treating oncologist's approval. ^R5–R9
• Tested athletes: Getting a wellness-clinic IV drip in a standard saline bag violates WADA's M2.2 intravenous infusion rule even though glutathione itself is permitted. ^R21
• Pregnant or breastfeeding women and children: Outside specific hospital obstetric uses on Japan's legacy prescription label (hyperemesis gravidarum), cosmetic or wellness injectable glutathione has not been studied for safety in pregnancy or lactation. ^{R15, R18}

---

7. Open questions and research gaps

• No large Phase 3 oncology survival trial: Although four small randomized trials (280 patients total) found that IV glutathione reduced cisplatin or oxaliplatin neuropathy without lowering short-term tumor response, regulators in the United States have not approved it because large Phase 3 trials powered to rule out any long-term effect on cancer survival have not been completed. ^{R5–R9, R20}
• Why intranasal and IV trials failed to beat placebo in Parkinson's disease: Blood and nasal delivery may not raise reduced glutathione inside vulnerable midbrain dopamine neurons enough to alter symptoms, or placebo responses in short Parkinson's trials may mask small effects. ^R2–R4
• Zero controlled human data for subcutaneous wellness injections: Despite being one of the most widely sold gray-market and med-spa injectables, subcutaneous glutathione has no randomized human trials for fatigue, "detox," immunity, or recovery.

---

8. References

• ^R1 Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(7):1159–1170. PMID 8938817 · doi:10.1016/s0278-5846(96)00103-0
• ^R2 Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009;24(7):979–983. PMID 19230029 · doi:10.1002/mds.22401
• ^R3 Mischley LK, Leverenz JB, Lau RC, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Mov Disord. 2015;30(12):1696–1701. PMID 26230671 · PMC4609266 · doi:10.1002/mds.26351
• ^R4 Mischley LK, Lau RC, Shankland EG, Wilbur TK, Padowski JM. Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. J Parkinsons Dis. 2017;7(2):289–299. PMID 28436395 · PMC5438472 · doi:10.3233/JPD-161040
• ^R5 Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol. 1995;13(1):26–32. PMID 7799029 · doi:10.1200/JCO.1995.13.1.26
• ^R6 Smyth JF, Bowman A, Perren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997;8(6):569–573. PMID 9261526 · doi:10.1023/a:1008211226339
• ^R7 Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20(16):3478–3483. PMID 12177109 · doi:10.1200/JCO.2002.07.061
• ^R8 Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs. 2009;20(5):396–402. PMID 19287306 · doi:10.1097/CAD.0b013e32832a2dc1
• ^R9 Leal AD, Qin R, Atherton PJ, et al.; Alliance for Clinical Trials in Oncology. North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer. 2014;120(12):1890–1897. PMID 24619793 · PMC4047184 · doi:10.1002/cncr.28654
• ^R10 Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23(2):97–102. PMID 20524875 · doi:10.3109/09546631003801619
• ^R11 Watanabe F, Hashizume E, Chan GP, Kamimura A. Skin-whitening and skin-condition-improving effects of topical oxidized glutathione: a double-blind and placebo-controlled clinical trial in healthy women. Clin Cosmet Investig Dermatol. 2014;7:267–274. PMID 25378941 · PMC4207440 · doi:10.2147/CCID.S68424
• ^R12 Handog EB, Datuin MS, Singzon IA. An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. Int J Dermatol. 2016;55(2):153–157. PMID 26148180 · doi:10.1111/ijd.12999
• ^R13 Weschawalit S, Thongthip S, Phutrakool P, Asawanonda P. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017;10:147–153. PMID 28490897 · PMC5413479 · doi:10.2147/CCID.S128339
• ^R14 Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. 2018;8(1):15–21 (including Table 1 appraisal of Zubair S, Hafeez S, Mujtaba G, J Pak Assoc Dermatol 2016;26:177–181, and Sonthalia S, Daulatabad D, Sarkar R, Indian J Dermatol Venereol Leprol 2016;82(3):262–272, PMID 27088927). PMID 29445569 · PMC5808366 · doi:10.5826/dpc.0801a04
• ^R15 Aloraini K, Alangari A, Arif J, Alkhodairy F. Glutathione for skin lightening via intravenous, oral, and topical routes: a critical narrative review of current evidence, safety, and the evidence-practice gap. J Med Life. 2026;19(7):511–523. PMID 42751591 · PMC13580517 · doi:10.25122/jml-2026-0054
• ^R16 Honda Y, Kessoku T, Sumida Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17(1):96. PMID 28789631 · PMC5549431 · doi:10.1186/s12876-017-0652-3
• ^R17 Griese M, Kappler M, Eismann C, et al.; Glutathione Study Group. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 2013;188(1):83–89. PMID 23631796 · doi:10.1164/rccm.201303-0427OC
• ^R18 Japan Pharmaceuticals and Medical Devices Agency (PMDA) & KEGG Drug Database. Tathion for Injection (タチオン注射用, glutathione), marketing approval nos. 21800AMX10590000 and 21800AMX10591000 (Choseido Pharmaceutical / Nihon Generic; package insert revised Sept 2024). PMDA Package Insert · JAPIC Entry · KEGG Drug D00014
• ^R19 Food and Drug Administration Philippines. Public Warning on the Unsafe Use of Glutathione as Skin-Lightening Agent: FDA Advisory No. 2011-004 (May 12, 2011) and FDA Advisory No. 2019-182 (July 2019).
• ^R20 US Food and Drug Administration (FDA). Compounding status, PCAC review, endotoxin alerts, and recalls for glutathione: 503A Bulk Drug Substances List (Category 1, updated May 14, 2026); 503B Bulk Drug Substances List (Category 1, updated Mar 21, 2025); June 8, 2022 PCAC Meeting Transcript; FDA 2019 Dietary-Ingredient Glutathione Endotoxin Alert; FDA Aug 27, 2026 Endotoxin Alert (30+ patients); Oct 1, 2026 Greenwich Rx Nationwide Recall; and FDA Consumer Update on Injectable Skin-Lightening Products.
• ^R21 World Anti-Doping Agency (WADA). 2026 Prohibited List — International Standard, Method M2.2 (Chemical and Physical Manipulation: intravenous infusions/injections rule; effective Jan 1, 2026).

---

Disclaimer

This page is for education and harm reduction. It is not medical advice and not a recommendation to use this compound. Please talk to a clinician you trust before making medical decisions, and report adverse events to FDA MedWatch (https://www.fda.gov/safety/medwatch).